US-based Organogenesis will introduce new PuraPly wound management products at the American Podiatric Medical Association (APMA) Annual Scientific Meeting, which is being held from 23 to 26 July.
The new products being launched include PuraPly and PuraPly Antimicrobial (PuraPly AM), which are the new additions to the firm’s portfolio of advanced wound-care products.
PuraPly AM is claimed to be the first FDA-cleared purified collagen matrix with polyhexamethylene biguanide hydrochloride (PHMB) antimicrobial agent.
Both FDA 510(k)-cleared Class II medical devices have received approval for acute and chronic wound management across different wound types such as partial and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers.
Organogenesis president and CEO Gary Gillheeney said: "With the addition of the PuraPly wound management products to our portfolio, we now offer clinicians products to treat wounds immediately when they enter their wound centers.
"Importantly, with PuraPly Antimicrobial, physicians have a treatment option for wounds with a high degree of bioburden."
Both products are available in different sizes that will meet the needs of a variety of wound types.